Phaseline

Targets › CFI

CFI (Complement factor I): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Sep 2028.

Trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways. Inhibits these pathways by cleaving three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins. (UniProt, P05156)

Open in Phaseline: the race on CFI, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Purespring TherapeuticsPS-002
Adeno-associated viral vector delivering Complement Factor I (CFI) gene to correct complem
CFIPhase 1Immunoglobulin A (IgA) NephropathySep 2028

Conditions

Immunoglobulin A (IgA) Nephropathy (1)

Modalities

other (1)

Companies

Purespring Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.